129482-45-7

Basic information

• Product Name: 4-benzyl-2-(chloromethyl)-1,4-oxazepane(SALTDATA: FREE)
• Synonyms: 4-benzyl-2-(chloromethyl)-1,4-oxazepane(SALTDATA: FREE);4-Benzyl-2-(chloromethyl)homomorpholine;4-benzyl-2-(chloromethyl)-1,4-oxazepane
• CAS NO: 129482-45-7
• Molecular Formula: C₁₃H₁₈ClNO
• Molecular Weight: 239.74112
• Mol File: 129482-45-7.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: 4-benzyl-2-(chloromethyl)-1,4-oxazepane(SALTDATA: FREE)(CAS DataBase Reference)
• NIST Chemistry Reference: 4-benzyl-2-(chloromethyl)-1,4-oxazepane(SALTDATA: FREE)(129482-45-7)
• EPA Substance Registry System: 4-benzyl-2-(chloromethyl)-1,4-oxazepane(SALTDATA: FREE)(129482-45-7)

Safety Data

• Hazardous Substances Data: 129482-45-7(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
4-Benzyl-2-(chloromethyl)-1,4-oxazepane (SALTDATA: FREE) is used as a chemical intermediate for the preparation of other substances. Its unique molecular structure, including the benzyl group, oxazepane ring, and chloromethyl group, makes it a valuable building block in the synthesis of various compounds.
Used in Pharmaceutical Industry:
4-Benzyl-2-(chloromethyl)-1,4-oxazepane (SALTDATA: FREE) is used as a starting material or a key component in the development of new pharmaceuticals. Its reactivity and unique molecular structure can be exploited to design and synthesize novel drug candidates with potential therapeutic applications.
Used in Material Science:
4-Benzyl-2-(chloromethyl)-1,4-oxazepane (SALTDATA: FREE) is used as a component in the development of new materials with specific properties. Its molecular structure and reactivity can contribute to the creation of materials with tailored characteristics for various applications, such as in electronics, coatings, or adhesives.
Used in Research and Development:
4-Benzyl-2-(chloromethyl)-1,4-oxazepane (SALTDATA: FREE) is used as a research compound in academic and industrial laboratories. Its unique properties and reactivity make it an interesting subject for studying chemical reactions, exploring new synthetic routes, and investigating potential applications in various fields.

Upstream product

• 73037-90-8 3-<(4-chlorobenzyl)amino>-1-hydroxypropane 
• 4720-29-0 3-(benzylamino)propan-1-ol 
• 309747-68-0 3-[Benzyl-(3-chloro-2-hydroxy-propyl)-amino]-propan-1-ol 

Downstream Products

• 1174020-52-0 tert-butyl 2-(hydroxymethyl)-1,4-oxazepane-4-carboxylate 
• 1031442-66-6 (4-benzyl-1,4-oxazepan-2-yl)methanol 
• 1207254-23-6 (1,4-oxazepan-2-yl)methanol 
• 309747-70-4 (4-benzyl-1,4-oxazepan-2-ylmethyl)-phenyl amine 
• 112925-36-7 2-(aminomethyl)-4-benzylhexahydro-1H-1,4-oxazepine 
• 129482-46-8 4-benzyl-2-(phthalimidomethyl)hexahydro-1,4-oxazepine 

Relevant articles and documents

Method of treating addiction or dependence using a ligand for a monoamine receptor or transporter

One aspect of the present invention relates to a method of treating of drug addiction or drug dependence in a mammal, comprising the step of administering to a mammal in need thereof a therapuetically effective amount of a heterocyclic compound, e.g., a 3-substituted piperidine. In a preferred embodiment, the method of the present invention treats cocaine addiction or methamphetamine addiction.

Ligands for monoamine receptors and transporters, and methods of use thereof

One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine, serotonin, or norepinephrine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, schizophrenia, Parkinson's disease, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.

Heterocyclic analgesic compounds and methods of use thereof

One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-coupled receptors, and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds as analgesics.

Heterocyclic analgesic compounds and methods of use thereof

One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-coupled receptors, and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds as analgesics.

Heterocyclic analgesic compounds and methods of use thereof

One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-coupled receptors, and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds as analgesics.

Disubstituted morpholine, oxazepine or thiazepine derivatives, their preparation and their use as dopamine D4 receptor antagonists

The present invention relates to compounds of formula (I), any of it enantiomers, or any mixture thereof, or a pharmaceutically acceptable acid addition salt thereof, wherein R1, R2, R3, R4, R11, R12, R13, R14and R15each independently are hydrogen, alkyl, alkoxy, halogen, trifluoromethyl, nitro, cyano, amino, acyl, alkylamino, dialkylamino, aminocarbonyl, or acylamino; R5 is hydrogen, alkyl, alkoxyalkyl, or phenylalkyl; X is —CH2—Z—, Z—CH2—, NH—CO—, —CO—NH—, or —CH═CH—; wherein Z is O, S, CH2, or NH; Y is O, —CH2—W—, —W—CH2—; wherein W is O, or S; and n is 0, 1 or 2. The compounds are useful in the treatment of psychotic disorders.

Quinolone antimicrobial agents substituted with morpholines at the 7- position. Syntheses and structure-activity relationships

A series of novel 7-substituted 1-cyclopropyl-6,8-difluoro-1,4-dihydro-4- oxo-3-quinolinecarboxylic acids have been prepared and tested for antibacterial activities and for convulsive activities in combination with nonsteroidal antiinflammatory drug. Stru